PIR (Pirin)

Targeting this pathway, either by pharmacologic inhibition of PLA2G4A with AACOCF3 or by genetic disruption of the PIR-PLA2G4A axis, enhances the efficacy of ferroptosis inducers and suppresses CRC progression. This study defines an NRF2-PIR-PLA2G4A circuit that governs ferroptosis susceptibility via lipidome remodeling and highlights its therapeutic potential in CRC.

Over-expression of piR-19521 enhanced CR-CSC markers expression, promoted clonogenicity, migration, invasion, oxaliplatin resistance in vitro, and increased tumorigenicity and liver metastasis in vivo...piR-19521 over-expression enhanced enhancer activity and ALX4 transcription. Collectively, these findings demonstrate that piR-19521 reinforces CR-CSC-like properties by functioning as an enhancer RNA to promote ALX4 expression, highlighting its potential as a therapeutic target in CRC.

In summary, our study revealed that piR-35410 promotes the malignant progression of TNBC by regulating PFKL-mediated glycolysis. These findings provide valuable insights into the role of piR-35410 in TNBC pathogenesis, revealing its potential as a novel therapeutic target.

Overall, our study uncovered the METTL3/IGF2BP3 (m6A)-PIR-WDR5 (H3K4me3)-ANAPC10 axis, bridging RNA methylation and histone methylation in UM pathogenesis. By unmasking these intricate epigenetic interactions, we provided novel insights into UM biology and identified potential therapeutic targets for tumor treatment, offering the theoretical support for future drug development and clinical applications.

piR-38,736 may serve as a prognostic biomarker and a potential therapeutic target for gastric cancer. Further studies are required to fully elucidate the underlying mechanisms of piR-38,736 and explore its clinical implications in gastric cancer management.

Additionally, ago-piR-26441 suppressed tumor growth and mitochondrial metabolism in the patient-derived organoid model. Altogether, piR-26441 could inhibit OC cell growth via the YTHDC1/TSFM signaling axis, underscoring its significant importance in the context of OC, as well as offering potential as a therapeutic target.

This study introduces pir-hsa-216911 as a new high-expressing piRNA in HCC, which inhibits pyroptosis by silencing TLR4 to suppress GSDMD activation. These findings have significant implications for HCC molecular subtyping and as a potential target for cancer therapy.

These effects could be mediated by modulating the NF-κB, SIRT1, NGF, and neuregulin-1 pathways. Pir is a promising agent for treating MS.

These findings highlight the functional importance of piR-hsa-23533 in HNSCC and may assist in the development of anti-HNSCC therapeutic target.

In summary, we showed that piR-1919609 is involved in the regulation of drug resistance in ovarian cancer cells and might be an ideal potential target for reversing platinum resistance in ovarian cancer.

Our systematic review and meta-analysis of piRNA-823 has important implications for cancer survivors. Our findings suggest that piRNA-823 can be used as a prognostic biomarker for predicting cancer recurrence and survival rates. This information can help clinicians develop personalized treatment plans for cancer survivors, which can improve their quality of life and reduce the risk of recurrence.

P=N/A, N=56, Active, not recruiting, Ain Shams University